MX2010009782A - Tratamientos antitumorales mejorados. - Google Patents

Tratamientos antitumorales mejorados.

Info

Publication number
MX2010009782A
MX2010009782A MX2010009782A MX2010009782A MX2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A MX 2010009782 A MX2010009782 A MX 2010009782A
Authority
MX
Mexico
Prior art keywords
improved antitumoral
antitumoral treatments
treatments
improved
combinations
Prior art date
Application number
MX2010009782A
Other languages
English (en)
Inventor
Santiago Ramon Y Cajal Agueeras
Javier Hernandez Losa
Jose Ma Jimeno Donaque
Eric Raymond
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2010009782A publication Critical patent/MX2010009782A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a combinaciones de PM02734 con otro fármaco anticancerígeno seleccionado de cisplatino, gemcitabina, paclitaxel, oxaliplatino, 5-fluorouracilo, trabectedina, rapamicina y sunitinib, y al uso de estas combinaciones en el tratamiento del cáncer.
MX2010009782A 2008-03-07 2009-03-06 Tratamientos antitumorales mejorados. MX2010009782A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380078 2008-03-07
PCT/EP2009/052649 WO2009109649A1 (en) 2008-03-07 2009-03-06 Improved antitumoral treatments

Publications (1)

Publication Number Publication Date
MX2010009782A true MX2010009782A (es) 2010-09-30

Family

ID=40627578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009782A MX2010009782A (es) 2008-03-07 2009-03-06 Tratamientos antitumorales mejorados.

Country Status (11)

Country Link
US (1) US20110015135A1 (es)
EP (1) EP2262522A1 (es)
JP (1) JP2011513370A (es)
KR (1) KR20100126479A (es)
CN (1) CN101965192A (es)
AU (1) AU2009221120A1 (es)
CA (1) CA2717117A1 (es)
IL (1) IL208000A0 (es)
MX (1) MX2010009782A (es)
RU (1) RU2010140890A (es)
WO (1) WO2009109649A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
WO2014010742A1 (ja) * 2012-07-13 2014-01-16 学校法人神戸学院 モノガラクトシルジアシルグリセロール又はその薬学的に許容し得る塩を有効成分として含む医薬組成物又は食品組成物
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020159171A2 (ko) * 2019-02-01 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JP3854306B2 (ja) * 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PT912559E (pt) * 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
EA003786B1 (ru) * 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
SK286421B6 (sk) * 2000-10-31 2008-09-05 Pharma Mar, S. A. Prostriedok kahalalid F, súprava, rekonštituovanýa zriedený roztok s obsahom tohto prostriedku a použitie
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
CN101077885A (zh) * 2002-10-18 2007-11-28 马尔药品公司 新型抗肿瘤化合物
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
WO2005072893A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
HUE028055T2 (en) * 2006-02-28 2016-11-28 Pharma Mar Sa Improved treatment of myeloma multiplex
NZ584695A (en) * 2007-10-19 2011-06-30 Pharma Mar Sa Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)

Also Published As

Publication number Publication date
CA2717117A1 (en) 2009-09-11
AU2009221120A1 (en) 2009-09-11
US20110015135A1 (en) 2011-01-20
JP2011513370A (ja) 2011-04-28
IL208000A0 (en) 2010-12-30
RU2010140890A (ru) 2012-04-20
EP2262522A1 (en) 2010-12-22
CN101965192A (zh) 2011-02-02
WO2009109649A1 (en) 2009-09-11
KR20100126479A (ko) 2010-12-01

Similar Documents

Publication Publication Date Title
MX2010009782A (es) Tratamientos antitumorales mejorados.
CY1118216T1 (el) Μεθοδοι αγωγης καρκινου
PH12016502066A1 (en) Methods of treating bladder cancer
MX342250B (es) Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
MX2013000779A (es) Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
IN2012DN02018A (es)
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
PT2155188E (pt) Métodos e composições para o tratamento de cancro recorrente
CL2007002640A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
MA33810B1 (fr) Compositions pour traiter les nausées et vomissements à médiation centrale
PH12018501339A1 (en) Combination therapy
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2009143454A3 (en) Combination antitumor therapy
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
MX2015003343A (es) Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico.
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
MX2010000223A (es) Compuestos de triazina novedosos para el tratamiento de cancer.
WO2010062143A3 (ko) Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를 포함하는 항암용 조성물
MX2010009697A (es) Tratamientos anticancerigenos mejorados.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal